| Bioactivity | Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors[1]. |
| Target | GDF-15 |
| Name | Visugromab |
| CAS | 2556646-63-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023. |